Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Rhea-AI Summary

On April 14, 2023, Akari Therapeutics (Nasdaq: AKTX) announced a virtual key opinion leader event scheduled for May 22, 2023, at 2 PM ET. This session will delve into the treatment landscape for geographic atrophy (GA) and the potential of long-acting PAS-nomacopan, an investigational therapy aimed at addressing significant unmet needs in this area. The event will feature Dr. Elias Reichel from Tufts University School of Medicine, who will discuss the development program for PAS-nomacopan. Following the presentations, a live Q&A session will be held. Interested individuals can register for the event through the provided link, and a replay will be available on the Akari website.

Akari Therapeutics is focused on developing advanced therapies for autoimmune and inflammatory diseases, with nomacopan as its lead asset. The company has received various designations for nomacopan related to its pediatric healthcare applications.

• Event on May 22^nd will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University School of Medicine

NEW YORK and LONDON, April 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will host a virtual key opinion leader event on May 22, 2023 at 2 pm ET to discuss the treatment landscape in geographic atrophy (GA) and the potential for long-acting PAS-nomacopan to address significant unmet needs. Akari’s lead asset is investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4). Long-acting PAS-nomacopan is currently in pre-clinical development as a potential treatment for GA.

The webinar event will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University School of Medicine. Dr. Reichel is also a scientific advisor to Akari. The Akari management team will present an overview and update on the development program investigating long-acting PAS-nomacopan in GA.

A live question and answer session will follow the formal presentations. To register for the event, click here. A replay will be available after the event at www.akaritx.com.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA. Akari’s pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product candidates and unexpected costs that may result there; difficulties enrolling patients in our clinical trials; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

For more information

Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
mmoyer@lifesciadvisors.com

Media Contact:
Eliza Schleifstein
Schleifstein PR 
(917) 763-8106
eliza@schleifsteinpr.com

FAQ

What is the date and time of the Akari Therapeutics event?

The Akari Therapeutics event is on May 22, 2023, at 2 PM ET.

Who will speak at the Akari Therapeutics virtual event?

Dr. Elias Reichel, a Professor at Tufts University School of Medicine, will speak at the event.

What is the focus of the Akari Therapeutics event?

The event will focus on the treatment landscape for geographic atrophy and the potential of long-acting PAS-nomacopan.

How can I register for the Akari Therapeutics event?

You can register for the event through the link provided in the press release.

What is nomacopan and its significance in the Akari Therapeutics pipeline?

Nomacopan is an investigational bispecific inhibitor designed to address autoimmune and inflammatory diseases, currently in development for pediatric and adult healthcare applications.